August 22, 2025CancersOpen Access

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials

View Full Paper

Ask AI

Bookmark

Authors

SBSabrina BakogeorgouNational and Kapodistrian University of Athens CFCharalampos FilippatosNational and Kapodistrian University of Athens PMPanagiotis MalandrakisNational and Kapodistrian University of Athens

Discussion

Member takes

Implication

Systematic review reports overall response rate of 69% in patients with relapsed multiple myeloma, suggesting bispecific antibodies are effective but with notable toxicity rates.

Key Points

BsAbs achieved a pooled overall response rate of 69%, indicating a significant impact on treatment outcomes for relapsed/refractory multiple myeloma.
The analysis involved 850 patients across six clinical trials, with a notable complete response rate of 42%, supporting their clinical utility.
Systematic review and meta-analysis utilized data from four studies revealing a pooled MRD-negativity rate of 24%, highlighting treatment effectiveness.
Despite commendable efficacy, notable hematological toxicity was observed, with neutropenia reported in 46% of patients, emphasizing the need for management strategies.

Cite This Study

Bakogeorgou et al. (2025) studied this question.

synapsesocial.com/papers/68af73567567bf4f94fec905 https://doi.org/10.3390/cancers17172727

View Full Paper

Ask AI

Bookmark

Implication

Systematic review reports overall response rate of 69% in patients with relapsed multiple myeloma, suggesting bispecific antibodies are effective but with notable toxicity rates.

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider